BIOGEN INC (IDP.DE) Stock Price & Overview
FRA:IDP • US09062X1037
The current stock price of IDP.DE is 156.7 EUR. Today IDP.DE is down by -3.42%. In the past month the price decreased by -4.6%. In the past year, price increased by 11.65%.
IDP.DE Key Statistics
- Market Cap
- 22.997B
- P/E
- 11.91
- Fwd P/E
- 11.97
- EPS (TTM)
- 13.16
- Dividend Yield
- N/A
IDP.DE Stock Performance
IDP.DE Stock Chart
IDP.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to IDP.DE. When comparing the yearly performance of all stocks, IDP.DE turns out to be only a medium performer in the overall market: it outperformed 58.4% of all stocks.
IDP.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE. IDP.DE has an excellent financial health rating, but there are some minor concerns on its profitability.
IDP.DE Earnings
On February 6, 2026 IDP.DE reported an EPS of 1.99 and a revenue of 2.28B. The company beat EPS expectations (20.87% surprise) and beat revenue expectations (1.26% surprise).
IDP.DE Forecast & Estimates
43 analysts have analysed IDP.DE and the average price target is 177.03 EUR. This implies a price increase of 12.97% is expected in the next year compared to the current price of 156.7.
For the next year, analysts expect an EPS growth of -0.5% and a revenue growth -3.97% for IDP.DE
IDP.DE Groups
Sector & Classification
IDP.DE Financial Highlights
Over the last trailing twelve months IDP.DE reported a non-GAAP Earnings per Share(EPS) of 13.16. The EPS decreased by -7.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.07% | ||
| ROA | 4.39% | ||
| ROE | 7.08% | ||
| Debt/Equity | 0.34 |
IDP.DE Ownership
IDP.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 24.06 | 38.751B | ||
| ARGX | ARGENX SE | 24.11 | 38.739B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.871B | ||
| ABVX | ABIVAX SA | N/A | 7.836B | ||
| 2X1 | ABIVAX SA | N/A | 7.812B | ||
| GXE | GALAPAGOS NV | N/A | 1.904B | ||
| GLPG | GALAPAGOS NV | N/A | 1.899B | ||
| NANO | NANOBIOTIX | N/A | 1.396B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| IVA | INVENTIVA SA | N/A | 1.096B | ||
| PHIL | PHILOGEN SPA | 17.21 | 614.04M | ||
| GNFT | GENFIT | N/A | 437.275M | ||
| AYJ | VALNEVA SE | N/A | 417.758M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About IDP.DE
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Company Info
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS US
Employees: 7500
Phone: 13023513367
BIOGEN INC / IDP.DE FAQ
What does BIOGEN INC do?
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
What is the current price of IDP stock?
The current stock price of IDP.DE is 156.7 EUR. The price decreased by -3.42% in the last trading session.
Does IDP stock pay dividends?
IDP.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of IDP stock?
IDP.DE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for IDP.DE stock?
43 analysts have analysed IDP.DE and the average price target is 177.03 EUR. This implies a price increase of 12.97% is expected in the next year compared to the current price of 156.7.
Can you provide the sector and industry classification for BIOGEN INC?
BIOGEN INC (IDP.DE) operates in the Health Care sector and the Biotechnology industry.